A Phase 1/2 interventional study of AZD3632 and Posaconazole in Acute Lymphoblastic Leukaemia, Acute Myeloid Leukaemia and Higher-risk Myelodysplastic Syndromes, sponsored by AstraZeneca. Recruiting at 30 sites in 9 countries. Open to participants aged 16 Years and older. Per ClinicalTrials.gov, last updated 2026-10-23.
Sponsored by AstraZeneca · Phase 1/2, Interventional, and Treatment
Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →
Among 1,545 studies in Precursor Cell Lymphoblastic Leukemia-Lymphoma with a site in United States — 171 open to participants now, 277 under way, 13 of them phase 3. Precursor Cell Lymphoblastic Leukemia-Lymphoma · United States.
Among the 1,545 studies in Precursor Cell Lymphoblastic Leukemia-Lymphoma with a site in United States, this one is the 251st largest by planned enrollment of the 1,269 interventional ones that give a count, is one of 39 that started in 2026, is one of 153 in phase 1/2, reaches primary completion later than 221 of the 275 other live ones, and was the 1,507th registered.
2,585 studies on the registry are indexed under Precursor Cell Lymphoblastic Leukemia-Lymphoma; 474 are open to participants now.
Browse Precursor Cell Lymphoblastic Leukemia-Lymphoma studies →171 of the 1,545 studies in Precursor Cell Lymphoblastic Leukemia-Lymphoma with a site in United States are open now. Recruiting first, the newest first:
Wake Forest University Health Sciences · Sites in United States
Ages 18+
St. Jude Children's Research Hospital · Sites in United States
Ages 8–18 · Healthy volunteers
National Cancer Institute (NCI) · Sites in United States
Ages 1–25
National Cancer Institute (NCI) · Sites in United States
Ages 18–120
Children's Hospital of Orange County · Sites in United States
Ages 0–18
A study can be open while its sites in United States have not opened yet or have stopped. Only those recruiting at a site in United States →
Of the 371 Precursor Cell Lymphoblastic Leukemia-Lymphoma studies recruiting now, 96 (26%) set no upper age limit and 258 (70%) stop at 75 or younger; 248 take children under 18; 29 take healthy volunteers.
This study: 16 Years and older · all sexes · no healthy volunteers.
The full table on the hub →This tab as a report to print or save as PDF → With an account.
1,545 studies; the count open now beside each. This study's row is marked.
A study in two phases is counted once above. Listed by phase, each with its combined phases: Phase 1 653 · Phase 2 593 · Phase 3 107 · Phase 4 10
First in 1984; this study’s year is marked. 39 started in 2026.
By drug class, each counting the studies that test any of its medicines:
This study's planned enrollment of 85 is above the median of 40 across 1,952 interventional studies indexed under Precursor Cell Lymphoblastic Leukemia-Lymphoma.
Median enrollment 35 across the 1,269 interventional studies, 110 across the 154 observational. Of the 1,180 that completed or were terminated, 437 (37%) have results posted.
This tab as a report to print or save as PDF → With an account.
213 of 1,545 have an industry lead sponsor. The 10 most frequent:
AstraZeneca is the lead sponsor of 3,503 studies on the registry; 273 are open to participants now.
Of its 369 completed or terminated interventional studies of FDA-regulated products, 178 (48%) have results posted.
AstraZeneca has 6 studies filed under Precursor Cell Lymphoblastic Leukemia-Lymphoma — fewer than ten, so there is no comparison to draw.
96 of the studies in Precursor Cell Lymphoblastic Leukemia-Lymphoma with a site in United States that are under way reach primary completion within a year, 3 of them phase 3. Phase 3 first, then by date:
| Study | Primary completion |
|---|---|
| NCT03020030Phase 3Dana-Farber Cancer InstituteTreatment of Newly Diagnosed Acute Lymphoblastic Leukemia in Children and Adolescents | 2026-11-30 |
| NCT03844048Phase 3AbbVieAn Extension Study of Venetoclax for Subjects Who Have Completed a Prior Venetoclax Clinical Trial | 2027-08 |
| NCT04851717Phase 3Acacia Pharma LtdInvestigation of Remimazolam in Children Undergoing Sedation for Medical Procedures | 2027-10 |
| NCT03104491Leland MethenyInotuzumab Ozogamicin Post-Transplant For Acute Lymphocytic Leukemia | 2026-11 |
| NCT06795126Nationwide Children's HospitalLittle NIRVANA for Pediatric Pain and Anxiety | 2026-11-30 |
Add all 96 to your calendar (.ics) → With an account.
Among the 1,545 studies in Precursor Cell Lymphoblastic Leukemia-Lymphoma with a site in United States, from their registry updates:
This tab as a report to print or save as PDF → With an account.
The purpose of this study is to understand the safety, tolerability, efficacy, pharmacokinetic (PK), pharmacodynamic (PD), and preliminary efficacy of orally administered AZD3632 in participants with advanced haematologic malignancies with KMT2Ar, NPM1m, or other genotypes associated with homeobox (HOX) overexpression.
This is a first in human (FTiH), open-label, multi-centre study of AZD3632 in participants with relapsed or refractory acute leukaemia or myelodysplastic Syndromes (MDS) with HOX overexpression genotypes.
This study includes multiple modules (module 1 and module 2) each investigating AZD3632 in a specific population and/or in combination with other anticancer agents.
Module 1 is a dose escalation of AZD3632 monotherapy. Module 2 will investigate the safety, PK, and tolerability when co-administered with posaconazole.
Key Inclusion Criteria:
Core criteria:
Module 1:
Module 2:
Key Exclusion Criteria:
Core criteria:
Module 1:
Module 2:
Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Ways of preventing pregnancy. “Highly effective” methods fail less than 1% of the time a year when used correctly — for example an IUD or an implant.
Criteria usually say which methods count and how long to keep using them after the last dose, sometimes for male participants too. Some studies accept a partner’s vasectomy if it was confirmed successful and that person is the participant’s only sexual partner.
Malignancy means cancer. Criteria about another or earlier malignancy ask whether you have had a different cancer, usually within a set number of years.
Some are commonly allowed, such as treated skin cancers other than melanoma and early cancers removed completely — check the exceptions this study lists.
The amount of disease can be tracked with a defined measurement, so the study can see whether it shrinks or grows. It might be a tumor measured on a scan or, in some blood cancers such as myeloma, a marker measured in blood or urine.
The criteria or the study team say which measurement counts — having no tumor visible on a scan does not by itself rule you out.
Relapsed: the illness came back after treatment had worked. Refractory: it did not respond to treatment, or stopped responding while still on it.
A scale of how much an illness limits everyday activity. For people being assessed to join a study, scores run from 0 (fully active) to 4; lower is more active.
Studies most often ask for 0–1 or 0–2. Your doctor gives the score; the WHO scale uses the same steps. The full scale also has 5, which records death.
The study doctor’s estimate of how long someone is likely to live. Criteria use it so that people can stay in the study long enough for it to answer its question.
A drug or device being studied in a clinical trial.
It may be new, or already approved and being studied for another use, dose or form. Criteria often leave out people who took part in another study of one within a recent period, commonly 30 days or five half-lives.
A reason a treatment, test or procedure should not be given to a particular person, such as an allergy, another illness or a medicine they take.
Contraception
Ways of preventing pregnancy. “Highly effective” methods fail less than 1% of the time a year when used correctly — for example an IUD or an implant.
Criteria usually say which methods count and how long to keep using them after the last dose, sometimes for male participants too. Some studies accept a partner’s vasectomy if it was confirmed successful and that person is the participant’s only sexual partner.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Cancer (malignancy)
Malignancy means cancer. Criteria about another or earlier malignancy ask whether you have had a different cancer, usually within a set number of years.
Some are commonly allowed, such as treated skin cancers other than melanoma and early cancers removed completely — check the exceptions this study lists.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Measurable disease
The amount of disease can be tracked with a defined measurement, so the study can see whether it shrinks or grows. It might be a tumor measured on a scan or, in some blood cancers such as myeloma, a marker measured in blood or urine.
The criteria or the study team say which measurement counts — having no tumor visible on a scan does not by itself rule you out.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Relapsed and refractory
Relapsed: the illness came back after treatment had worked. Refractory: it did not respond to treatment, or stopped responding while still on it.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
ECOG performance status
A scale of how much an illness limits everyday activity. For people being assessed to join a study, scores run from 0 (fully active) to 4; lower is more active.
Studies most often ask for 0–1 or 0–2. Your doctor gives the score; the WHO scale uses the same steps. The full scale also has 5, which records death.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Life expectancy
The study doctor’s estimate of how long someone is likely to live. Criteria use it so that people can stay in the study long enough for it to answer its question.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Investigational drug or device
A drug or device being studied in a clinical trial.
It may be new, or already approved and being studied for another use, dose or form. Criteria often leave out people who took part in another study of one within a recent period, commonly 30 days or five half-lives.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Contraindication
A reason a treatment, test or procedure should not be given to a particular person, such as an allergy, another illness or a medicine they take.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Participants will receive AZD3632 (dose 1) through the treatment period.
Drug: AZD3632
Participants will receive AZD3632 (dose 2) through the treatment period.
Drug: AZD3632
Participants will receive AZD3632 (dose 3) through the treatment period.
Drug: AZD3632
Participants will receive AZD3632 (dose 4) through the treatment period.
Drug: AZD3632
Participants will receive AZD3632 (dose 5) through the treatment period.
Drug: AZD3632
Participants will receive AZD3632 (dose 6) through the treatment period.
Drug: AZD3632
Participants will receive AZD3632 alone, then will receive AZD3632 in combination with posaconazole through treatment period.
Drug: AZD3632 · Drug: Posaconazole
AZD3632 will be administered orally.
Posaconazole will be administered orally.
Module 1: Number of participants with dose-limiting toxicity (DLT)
Safety and tolerability of AZD3632 monotherapy in participants with advanced haematologic malignancies will be assessed.
Time frame: At the end of Cycle 1 (each cycle is 28 days)
Module 1 and Module 2: Number of participants with dose modification, delay and discontinuations due to adverse events (AEs)
Safety and tolerability of AZD3632 monotherapy in participants with advanced haematologic malignancies will be assessed.
Time frame: Up to 3 years 1 month
Module 1 and Module 2: Number of participants with treatment-emergent adverse events (TEAEs), treatment-related AEs (TRAEs) and serious adverse vents (SAEs)
Safety and tolerability of AZD3632 monotherapy in participants with advanced haematologic malignancies will be assessed. Adverse events will be defined as treatment-emergent if they have an onset or worsen (by investigator report of a change in intensity) during the study treatment or the safety follow-up period but prior to any subsequent cancer therapy.
Time frame: Up to 30 days after last dose (approximately 3 years 1 month)
Module 1 and Module 2: Maximum concentration (Cmax) of AZD3632
The PK of AZD3632 as monotherapy (module 1) and in combination with posaconazole (module 2) will be assessed.
Time frame: From Day 1 to 3 years 1 month
Module 1 and Module 2: Time of maximum concentration (Tmax) of AZD3632
The PK of AZD3632 as monotherapy (module 1) and in combination with posaconazole (module 2) will be assessed.
Time frame: From Day 1 to 3 years 1 month
Module 1: Trough concentration (Ctrough) of AZD3632
The PK of AZD3632 as monotherapy will be assessed.
Time frame: From Day 1 to 3 years 1 month
Module 1: Area under the plasma concentration-time Curve from Time Zero to Infinity (AUC[inf]) of AZD3632
The PK of AZD3632 as monotherapy will be assessed.
Time frame: From Day 1 to 3 years 1 month
Module 1 and Module 2: Area under the curve from time 0 to the time of last measurable concentration (AUC[0-t]) of AZD3632
The PK of AZD3632 as monotherapy (module 1) and in combination with posaconazole (module 2) will be assessed.
Time frame: From Day 1 to 3 years 1 month
Module 1: Area under concentration-time curve in the dosing interval (AUCtau) of AZD3632
The PK of AZD3632 as monotherapy will be assessed.
Time frame: From Day 1 to 3 years 1 month
Module 1: Apparent total body clearance (CL/F) of AZD3632
The PK of AZD3632 as monotherapy will be assessed.
Time frame: From Day 1 to 3 years 1 month
Module 1: Apparent volume of distribution based on the terminal phase (VZ/F) of AZD3632
The PK of AZD3632 as monotherapy will be assessed.
Time frame: From Day 1 to 3 years 1 month
Module 1: Half-life (t1/2) of AZD3632
The PK of AZD3632 as monotherapy will be assessed.
Time frame: From Day 1 to 3 years 1 month
Module 1: Maximum concentration (Cmax) of AZD3632 (food effect)
The preliminary effect of food on plasma PK of AZD3632 (conducted in a nested evaluation during backfills) will be assessed.
Time frame: From Day 1 to 3 years 1 month
Module 1: Time of maximum concentration (Tmax) of AZD3632 (food effect)
The preliminary effect of food on plasma PK of AZD3632 (conducted in a nested evaluation during backfills) will be assessed.
Time frame: From Day 1 to 3 years 1 month
Module 1 and Module 2: Area under the curve from time 0 to the time of last measurable concentration (AUC[0-t]) of AZD3632 (food effect)
The preliminary effect of food on plasma PK of AZD3632 (conducted in a nested evaluation during backfills) will be assessed.
Time frame: From Day 1 to 3 years 1 month
Module 1: Area under concentration-time curve in the dosing interval (AUCtau) of AZD3632 (food effect)
The preliminary effect of food on plasma PK of AZD3632 (conducted in a nested evaluation during backfills) will be assessed.
Time frame: From Day 1 to 3 years 1 month
Module 1: Minimum concentration (Cmin) of AZD3632 (food effect)
The preliminary effect of food on plasma PK of AZD3632 (conducted in a nested evaluation during backfills) will be assessed.
Time frame: From Day 1 to 3 years 1 month
Module 1: Ratio of Cmax between fed and fasted state
The preliminary effect of food on plasma PK of AZD3632 (conducted in a nested evaluation during backfills) will be assessed.
Time frame: From Day 1 to 3 years 1 month
Module 1: Ratio of AUC(0-t) between fed and fasted state
The preliminary effect of food on plasma PK of AZD3632 (conducted in a nested evaluation during backfills) will be assessed.
Time frame: From Day 1 to 3 years 1 month
Module 1: Ratio of AUCtau between fed and fasted state
The preliminary effect of food on plasma PK of AZD3632 (conducted in a nested evaluation during backfills) will be assessed.
Time frame: From Day 1 to 3 years 1 month
Module 2: Plasma geometric mean ratio of Cmax
The PK pf AZD3632 when co-administered with posaconazole will be assessed.
Time frame: From Day 1 to 3 years 1 month
Module 2: Plasma geometric mean ratio of AUC
The PK pf AZD3632 when co-administered with posaconazole will be assessed.
Time frame: From Day 1 to 3 years 1 month
Module 2: Plasma concentration of posaconazole
The PK pf AZD3632 when co-administered with posaconazole will be assessed.
Time frame: From Day 1 to 3 years 1 month
Module 1 and Module 2: Complete response rate (CR + CRh)
Complete response rate is defined as the percentage of participants who have a complete remission (CR) or complete remission with partial haematological recovery (CRh) as assessed by the investigator at local site.
Time frame: Up to 3 years 1 month
Module 1 and Module 2: Time to response (TTR)
TTR in participants with acute leukaemia is defined as the time from date of first dose until date of first documented complete response (CR/CRh) among participants with acute leukaemia in the Response Evaluable Set who achieved complete response as assessed by investigator at local site. TTR in participants with MDS is defined as the time from date of first dose until date of first documented objective response a CR (or CR equivalent), complete response with limited count recovery \[CRL\], CRh, partial response \[PR\], or haematologic improvement \[HI\]) among participants with MDS in the Response Evaluable Set who achieved objective response as assessed by investigator at local site.
Time frame: Up to 3 years 1 month
Module 1 and Module 2: Duration of response (DoR)
DoR in participants with acute leukaemia is defined as the time from date of first documented complete response (CR/CRh) until date of first documented relapse or death (by any cause in the absence of relapse) as assessed by investigator at local site. DoR in participants with MDS is defined as the time from date of first documented objective response CR (or CR equivalent), CRL, CRh, PR, or HI until date of first documented relapse or death (by any cause in the absence of relapse) as assessed by investigator at local site.
Time frame: Up to 3 years 1 month
Module 1 and Module 2: Transfusion Independence (TI)
TI is defined as no RBC and no platelet transfusion during any consecutive period of at least 56 days post-baseline after starting treatment with AZD3632 or cessation of treatment with AZD3632 but prior to start of subsequent new therapy.
Time frame: Up to 3 years 1 month
Module 1 and Module 2: Event-free Survival (EFS)
EFS for participants with acute leukaemia is defined as the time from date of first dose until date of relapse, progressive disease, failure to achieve at least Morphologic leukaemia-free state (MLFS) by end of Cycle 6, or death due to any cause as assessed by investigator at a local site. EFS for participants with MDS is defined as the time from date of first dose until date of relapse, progressive disease, failure to achieve at least HI by end of Cycle 6, or death due to any cause.
Time frame: From Cycle 2 Day 1 (each cycle is 28 days) up to disease follow-up (approximately 3 years 1 month)
Module 1 and Module 2: Overall Survival (OS)
OS is defined as the time from date of first dose until date of death due to any cause regardless of whether the participant withdraws from study therapy or receives another anticancer therapy.
Time frame: From Cycle 2 Day 1 (each cycle is 28 days) up to disease follow-up (approximately 3 years 1 month)
Module 1 and Module 2: Percentage of participants who receive subsequent allogeneic hematopoietic stem cell transplant (HSCT)
Percentage of participants with acute leukaemia and MDS who receive subsequent allogeneic HSCT will be reported.
Time frame: Up to 3 years 1 month
Module 1 and Module 2: Overall Response Rate (ORR)
ORR in participants with myelodysplastic syndromes (MDS) is defined as the percentage of participants who have a CR (or CR equivalent), CRL, CRh, PR, or HI as determined by investigator at a local site.
Time frame: Up to 3 years 1 month
Module 1 and Module 2: Time to Progression to acute myeloid leukaemia (AML)
Time to progression to AML is defined from the time of first dose of AZD3632 until first diagnosis of AML, regardless of discontinuation of treatment or receiving of subsequent therapy.
Time frame: Up to 3 years 1 month
Not enrolling at this site — choose another above.
Not enrolling at this site — choose another above.
Not enrolling at this site — choose another above.
Not enrolling at this site — choose another above.
Not enrolling at this site — choose another above.
Not enrolling at this site — choose another above.
Plan to share: Yes — Qualified researchers can request access to anonymized individual patient-level data from AstraZeneca group of companies sponsored clinical trials via the request portalVivli.org. All requests will be evaluated as per the AZ disclosure commitment: https://astrazenecagrouptrials.pharmacm.com/ST/Submission/Disclosure."Yes", indicates that AZ are accepting requests for IPD, but this does not mean all requests will be shared.
Supporting information: Study protocol, Statistical analysis plan
Time frame: AstraZeneca will meet or exceed data availability as per the commitment a made to the EFPIA PhRMA Data-Sharing Principles. For details of our timelines, please refer to our disclosure commitment at https://astrazenecagrouptrials.pharmacm.com/ST/Submission/Disclosure.
Access criteria: When a request has been approved AstraZeneca will provide access to the anonymized individual patient-level data via secure research environment Vivli.org. Signed Data Usage Agreement (non-negotiable contract for data accessors) must be in place before accessing requested information.
Data sharing details ↗ · vivli.org
No publications or documents are linked to this record.
Started Jan 2026 (actual). Primary completion is estimated for Feb 2029, 37 months after the start.
Of 114 phase 1/2 interventional studies under Precursor Cell Lymphoblastic Leukemia-Lymphoma, half reached primary completion within 81 months of starting (the median), counting those still running; a quarter within 56 and three quarters within 119. This study's planned 37 months is below that.
How these figures are worked out, and which studies are left out of them.
From the registry record's own update history. This site started tracking changes on Sep 25, 2026; for anything earlier, see the record history on ClinicalTrials.gov ↗
Eligibility is decided by the study team. Share this record with your doctor or contact the team directly.
Contact study teamGet an email when the registry record changes — status, dates, results — or when someone posts here.
Sign in to followQuestions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.
Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.
Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.
Precursor Cell Lymphoblastic Leukemia-Lymphoma →